1331P Resistance mechanisms in EGFR-mutated advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with first-line osimertinib (osi) and monitoring plasma mutational l... von Bonanno, L., Ferro, A., Bao, L.C., Marinato, G.M., Padovan, A., Zulato, E., Frega, S., Dal Maso, A., Pasello, G., Indraccolo, S., Guarneri, V.

Volltext

106P Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi) von Bonanno, L., Bao, L.C., Padovan, A., Ferro, A., Bianco, A., Calvetti, L., Pavan, A., Ziampiri, S., Zulato, E., Marinato, G.M., Maso, A. Dal, Frega, S., Pasello, G., Guarneri, V., Indraccolo, S.

Volltext

1584P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) in a real-world analysis: A risk prediction nomogram von Ferro, A., Girardi, F., Pretelli, G., Mulargiu, C., Resi, M.V., Benetti, B., Marinato, G.M., Lorenzi, M., Dal Maso, A., Frega, S., Pasello, G., Guarneri, V., Bonanno, L.

Volltext

40P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): A real-world analysis von Pretelli, G., Pavan, A., Dal Maso, A., Resi, M.V., Mulargiu, C., Ferro, A., Benetti, B., Lorenzi, M., Marinato, G.M., Frega, S., Pasello, G., Conte, P.F., Guarneri, V., Bonanno, L.

Volltext

63P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): Neutrophil to lymphocyte ratio (NLR) and the risk for toxicity recurrence von Pretelli, G., Pavan, A., Dal Maso, A., Resi, M.V., Mulargiu, C., Ferro, A., Benetti, B., Lorenzi, M., Marinato, G.M., Frega, S., Pasello, G., Conte, P.F., Guarneri, V., Bonanno, L.

Volltext